公开(公告)号：US09802994B2

公开(公告)日：2017-10-31

申请号：US14408275

申请日：2013-06-14

Applicant: THE ASAN FOUNDATION

Inventor： Jung-Min Koh ,  Ghi Su Kim ,  Seung Hun Lee ,  Young-Sun Lee ,  Beom-Jun Kim

IPC: A61K38/17 ,  C07K14/47 ,  A61P19/10 ,  G01N33/68 ,  C07K14/705 ,  G01N33/50 ,  A23L33/195 ,  A61K38/00

CPC classification number: C07K14/47 ,  A23L33/195 ,  A23V2002/00 ,  A61K38/00 ,  A61K38/1709 ,  C07K14/4702 ,  C07K14/70503 ,  G01N33/5023 ,  G01N33/6893 ,  G01N2500/10 ,  G01N2800/108

Abstract: A pharmaceutical composition for preventing or treating a fracture or osteoporosis, includes, as an active ingredient, a gene selected from a group consisting of slit1, slit2, slit3, robo1, robo2 and vilse, or an expressed protein of the gene. A marker composition for predicting the risk of the occurrence of a fracture or osteoporosis includes the protein. A kit for predicting the risk of the occurrence of a fracture or osteoporosis includes an antibody that specifically binds to the protein. An information provision method for predicting the risk of the occurrence of a fracture or osteoporosis includes measuring the level of expression of the slit protein through an antigen-antibody binding reaction using an antibody that specifically binds to the protein. The slit3 may increase bone formation and decrease bone reabsorption in a cellular and animal model, and has a negative correlation with the incidence rate of osteoporosis.

公开(公告)号：US20150175673A1

公开(公告)日：2015-06-25

申请号：US14408275

申请日：2013-06-14

Applicant: THE ASAN FOUNDATION

Inventor： Jung-Min Koh ,  Ghi Su Kim ,  Seung Hun Lee ,  Young-Sun Lee ,  Beom-Jun Kim

IPC: C07K14/47 ,  A23L1/305 ,  G01N33/50

CPC classification number: C07K14/47 ,  A23L33/195 ,  A23V2002/00 ,  A61K38/00 ,  A61K38/1709 ,  C07K14/4702 ,  C07K14/70503 ,  G01N33/5023 ,  G01N33/6893 ,  G01N2500/10 ,  G01N2800/108

Abstract: A pharmaceutical composition for preventing or treating a fracture or osteoporosis, includes, as an active ingredient, a gene selected from a group consisting of slit1, slit2, slit3, robo1, robo2 and vilse, or an expressed protein of the gene. A marker composition for predicting the risk of the occurrence of a fracture or osteoporosis includes the protein. A kit for predicting the risk of the occurrence of a fracture or osteoporosis includes an antibody that specifically binds to the protein. An information provision method for predicting the risk of the occurrence of a fracture or osteoporosis includes measuring the level of expression of the slit protein through an antigen-antibody binding reaction using an antibody that specifically binds to the protein. The slit3 may increase bone formation and decrease bone reabsorption in a cellular and animal model, and has a negative correlation with the incidence rate of osteoporosis.

Abstract translation: 用于预防或治疗骨折或骨质疏松症的药物组合物包括作为活性成分的选自由狭缝1，狭缝2，裂缝3，robo1，robo2和vilse组成的组的基因或所述基因的表达蛋白质。 用于预测骨折或骨质疏松症发生风险的标记物组合物包括蛋白质。 用于预测骨折或骨质疏松症发生风险的试剂盒包括特异性结合蛋白质的抗体。 用于预测骨折或骨质疏松症发生风险的信息提供方法包括使用特异性结合蛋白质的抗体通过抗原 - 抗体结合反应来测定狭缝蛋白的表达水平。 狭缝3可能在细胞和动物模型中增加骨形成并减少骨重吸收，并与骨质疏松症的发生率呈负相关。